Arista Wealth Management LLC Invests $381,000 in Sanofi $SNY

Arista Wealth Management LLC purchased a new position in Sanofi (NASDAQ:SNY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,890 shares of the company’s stock, valued at approximately $381,000.

A number of other large investors have also recently made changes to their positions in SNY. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Sanofi by 58.7% in the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after acquiring an additional 2,241 shares during the period. Sowell Financial Services LLC bought a new stake in Sanofi during the first quarter valued at $328,000. Clarius Group LLC boosted its stake in Sanofi by 19.9% during the first quarter. Clarius Group LLC now owns 5,643 shares of the company’s stock valued at $313,000 after buying an additional 935 shares during the period. Finally, ORG Wealth Partners LLC bought a new stake in Sanofi during the first quarter valued at $91,000. 14.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Finally, Barclays reiterated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Stock Up 1.2%

SNY opened at $50.62 on Friday. The company has a market cap of $124.30 billion, a P/E ratio of 12.17, a P/E/G ratio of 1.22 and a beta of 0.51. The business’s 50-day moving average price is $48.49 and its 200-day moving average price is $49.63. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. During the same quarter in the prior year, the firm earned $1.73 EPS. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. On average, equities analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.